Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Colorado Prevention Center Clear all
Recruiting Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197
View directory record Official record
Conditions
Heart Failure, Acute Heart Failure
Interventions
Finerenone, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
5,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
82
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 26, 2026, 5:33 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Cilostazol in Combination With L-Carnitine

NCT00822172
View directory record Official record
Conditions
Peripheral Vascular Disease, Intermittent Claudication, Peripheral Arterial Disease
Interventions
Levocarnitine tartrate, cilostazol
Dietary Supplement · Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
40 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 26, 2026, 5:33 PM EDT
Active, not recruiting Phase 4 Interventional

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

NCT05284747
View directory record Official record
Conditions
Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions
Evolocumab, Routine Lipid Management
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
6,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 26, 2026, 5:33 PM EDT
Completed Not applicable Interventional

An Observational Study of the Functional Capacity of Heart Failure

NCT02350114
View directory record Official record
Conditions
Acute Heart Failure
Interventions
6 Minute Walk Test
Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Indianapolis, Indiana • Detroit, Michigan • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 26, 2026, 5:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Virta Intervention in CommuniTies in cOloRado (VICTOR-Pilot)

NCT04807218
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Virta Health
Behavioral
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years to 79 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Craig, Colorado • Lamar, Colorado • Salida, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 26, 2026, 5:33 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19

NCT04655586
View directory record Official record
Conditions
Covid19
Interventions
rNAPc2, Heparin
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Fairhope, Alabama • Phoenix, Arizona • Tucson, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 26, 2026, 5:33 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)

NCT00399919
View directory record Official record
Conditions
Peripheral Vascular Diseases, Intermittent Claudication
Interventions
Propionyl-L-Carnitine, PLC
Drug
Lead sponsor
Sigma-Tau Research, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Jacksonville, Florida • Pensacola, Florida • LaGrange, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Sep 26, 2026, 5:33 PM EDT
Recruiting Phase 4 Interventional

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
139
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 26, 2026, 5:33 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

NCT06033950
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
2,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
54
States / cities
Fairhope, Alabama • Phoenix, Arizona • Yuma, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 26, 2026, 5:33 PM EDT
Recruiting Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

NCT06024746
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone, Empagliflozin
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Fairhope, Alabama • Phoenix, Arizona • Chula Vista, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 26, 2026, 5:33 PM EDT
Withdrawn Phase 4 Interventional

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

NCT00657514
View directory record Official record
Conditions
Peripheral Arterial Disease, Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 14, 2014 · Synced Sep 26, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

NCT02504216
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
6,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
105
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 26, 2026, 5:33 PM EDT
Completed Not applicable Interventional Results available

The Respiratory Protection Effectiveness Clinical Trial

NCT01249625
View directory record Official record
Conditions
Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus, Rhinovirus
Interventions
N95 Respirator, Medical/surgical mask
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
2,862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
7
States / cities
Aurora, Colorado • Denver, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 26, 2026, 5:33 PM EDT
Completed Not applicable Interventional

Implementation of Vascular Care Team to Improve Medical Management of PAD Patients

NCT04400409
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Intervention A - Vascular Care + site 6MWT administration, Intervention B - Standard Care + site 6MWT administration, Intervention A - Vascular Care + CPC EQuIP 6MWT administration, Intervention B - Standard Care + CPC EQuIP 6MWT administration
Other
Lead sponsor
Colorado Prevention Center
Other
Eligibility
Not listed
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 26, 2026, 5:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study

NCT01825382
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
iBGStar meter
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Sep 26, 2026, 5:33 PM EDT
Recruiting Not applicable Interventional

Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease

NCT07334834
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Algorithm- and multi-professional team-supported lipid management, Guideline-directed lipid management by usual care provider
Other
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 26, 2026, 5:33 PM EDT